James Bradner joins Amgen as David Reese becomes chief tech officer

14 December 2023

Former Novartis (NOVN: VX) executive James Bradner has joined Amgen (Nasdaq: AMGN) as executive vice president of research and development (R&D), and chief scientific officer.

Dr Bradner, a seasoned R&D leader, is succeeding David Reese, who has been appointed executive vice president and chief technology officer at the US biotech major.

"The steps we are announcing today reflect our conviction that the rapid convergence of ‘biotech’ and ‘tech’ will unlock the next frontier of innovation"In his new role, Dr Bradner will be responsible for advancing Amgen’s pipeline. This includes medicines in all stages of development and across the company’s four therapeutic areas of focus, namely oncology, inflammation, general medicine and rare disease, in addition to biosimilars. He will also be responsible for the firm’s worldwide research efforts.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK